GlassScriptPhysician profile
Trevor J Resnick
NPI 1780641381
$229,587.74
in general payments reported to CMS, 2019-2025
35 companies · $6,153 in 2025
The $6,153 reported for 2025 was more than what 87% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $53K · 2021: $15K · 2022: $21K · 2023: $16K · 2024: $7,565 · 2025: $6,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Honoraria: $6,800 · Food and Beverage: $5,894 · Consulting Fee: $2,238 · Travel and Lodging: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,700.00 |
| Honoraria | $6,800.00 |
| Food and Beverage | $5,894.28 |
| Consulting Fee | $2,238.00 |
| Travel and Lodging | $1,464.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $93,948.30 | 2019-2023 | |
| Ucb, INC. | $35,380.36 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Mallinckrodt Enterprises LLC | $27,713.98 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19,219.08 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $11,507.60 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $8,392.18 | 2023-2025 | Fycompa |
| Supernus Pharmaceuticals, INC. | $7,954.48 | 2019-2023 | Qelbree |
| Sk Life Science, INC. | $5,280.95 | 2020-2023 | |
| Ucb Sa | $4,958.80 | 2019 | |
| Aquestive Therapeutics, INC. | $3,288.38 | 2019-2024 | |
| Hikma Pharmaceuticals USA | $3,000.00 | 2022 | |
| Azurity Pharmaceuticals, INC. | $2,548.47 | 2023-2025 | Eprontia, Zonisade |
| Jazz Pharmaceuticals INC. | $1,874.99 | 2022-2025 | Epidiolex |
| Otter Pharmaceuticals, LLC | $1,338.00 | 2024 | Sympazan |
| Neurelis, INC. | $811.34 | 2021-2025 | Valtoco |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $463.87 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sumitomo Pharma America, INC. | $368.26 | 2023 | Aptiom |
| Corium, LLC | $299.56 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $242.57 | 2019-2023 | Jornay Pm |
| Immedica Pharma US, INC. | $139.85 | 2022-2025 | Ztalmy |
| Greenwich Biosciences, INC. | $130.87 | 2019-2021 | |
| Biocodex, INC. | $127.41 | 2023-2025 | Diacomit |
| Aprecia Pharmaceuticals, LLC | $112.61 | 2022-2023 | Spritam |
| Biogen, INC. | $110.21 | 2022-2023 | Spinraza |
| Tris Pharma INC | $81.54 | 2019-2023 | Dyanavel Xr |
| Zogenix INC. | $48.63 | 2021 | |
| Aucta Pharmaceuticals, INC. | $47.21 | 2025 | Motpoly Xr |
| Novartis Pharmaceuticals Corporation | $45.47 | 2019-2021 | |
| Ns Pharma, INC. | $29.16 | 2021-2022 | |
| Abbvie INC. | $27.61 | 2023 | |
| Vertical Pharmaceuticals, LLC | $26.59 | 2019 | |
| Acadia Pharmaceuticals INC | $26.47 | 2025 | Daybue |
| Ipsen Biopharmaceuticals, INC | $16.49 | 2019 | |
| Piramal Critical Care | $13.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Resnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.